Clinical Trials Directory

Trials / Conditions / Childhood Oligodendroglioma

Childhood Oligodendroglioma

13 registered clinical trials studyying Childhood Oligodendroglioma.

StatusTrialSponsorPhase
CompletedSunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or E
NCT01462695
National Cancer Institute (NCI)Phase 2
TerminatedGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T
NCT01088763
National Cancer Institute (NCI)Phase 1
CompletedVorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spi
NCT01076530
National Cancer Institute (NCI)Phase 1
CompletedVorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Cent
NCT00994500
National Cancer Institute (NCI)Phase 1
CompletedABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
NCT00946335
National Cancer Institute (NCI)Phase 1
CompletedBevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medul
NCT00381797
National Cancer Institute (NCI)Phase 2
CompletedAZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
NCT00326664
National Cancer Institute (NCI)Phase 1
CompletedLenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
NCT00100880
National Cancer Institute (NCI)Phase 1
CompletedCollecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
NCT00919750
Children's Oncology Group—
CompletedTipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primit
NCT00070525
National Cancer Institute (NCI)Phase 2
CompletedCilengitide in Treating Children With Refractory Primary Brain Tumors
NCT00063973
National Cancer Institute (NCI)Phase 1
CompletedTemozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
NCT00052780
National Cancer Institute (NCI)Phase 1
CompletedIrinotecan in Treating Children With Refractory Solid Tumors
NCT00004078
Children's Oncology GroupPhase 2